SCHEMBL2948693

SCHEMBL2948693

CN(C)CCNc1cc(N2CCCCCC2)ncn1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 8/20 0.55
HRH3 Q9Y5N1 3/20 0.53
HRH2 P25021 1/20 0.53
DNM2 P50570 2/20 0.52
SMN1; SMN2 Q16637 3/20 0.46
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 1/20 0.44
PIK3CB P42338 1/20 0.43
AURKA O14965 1/20 0.43
KIT P10721 1/20 0.43
FLT3 P36888 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.42
MAP4K4 O95819 1/20 0.42
TSHR P16473 1/20 0.41
RECQL P46063 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5090089 0.79 HRH4 (0.55) HRH4HRH3HRH2SMN1; SMN2RAB9A
SCHEMBL4889132 0.76 HRH4 (0.47) HRH4HRH3HRH2DNM2AURKA
SCHEMBL17623030 0.76 HRH4 (0.52) HRH4HRH3HRH2SMN1; SMN2RAB9A
SCHEMBL5144566 0.75 NUDT1 (0.56) HRH4HRH3HRH2SMN1; SMN2RAB9A
SCHEMBL2567649 0.73 SMN1; SMN2 (0.54) HRH4HRH3HRH2SMN1; SMN2RAB9A
SCHEMBL12497656 0.73 DNM2 (0.62) HRH4HRH3DNM2MAP4K4CYP2C19
SCHEMBL1089965 0.73 CXCR4 (0.68) HRH4HRH3HRH2DNM2
SCHEMBL3477066 0.72 HRH4 (0.41) HRH4HRH3HRH2SMN1; SMN2
SCHEMBL1090467 0.72 ACHE (0.61) HRH3DNM2CYP2C19
SCHEMBL1089897 0.72 ACHE (0.61) HRH3DNM2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 HRH4 130/4885HRH3 94/4885HRH2 261/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 HRH4 130/4885HRH3 94/4885HRH2 261/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 HRH4 130/4885HRH3 94/4885HRH2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.